Up to 85% of women with early ER-positive, HER2-negative, node-negative breast cancer can be spared chemotherapy, according to results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. The TAILORx trial of more than 10,000 women found endocrine therapy alone was non-inferior to endocrine therapy plus chemotherapy in women with a midrange ...
Recurrence score guides chemo use
By Mardi Chapman
6 Jun 2018